Background: Cytomegalovirus (CMV) infection has been shown to be related to severe or steroid-refractory ulcerative colitis (UC) flare-ups. The aim
H uman cytomegalovirus (CMV) infection is common in the general population with a reported prevalence ranging from 40% to 100%. 1, 2 The high rate of viral latency of CMV makes its reactivation common in immunocompromised patients. 3, 4 This is especially true in patients with inflammatory bowel disease (IBD) who are under nourished and are often on immunosuppressive drugs, such as corticosteroids, thiopurines, or biologics. 5, 6 It has been reported that CMV was detected in colon tissue in 21% to 34% of patients with ulcerative colitis (UC) in general and 33% to 36% in those with steroid-refractory UC. 7, 8 Several studies have suggested a deleterious role of CMV reactivation in UC flare-ups, increasing the risk for steroid resistance, hospitalization, and need for colectomy. Kishore et al reported 40% of patient with CMV infection in IBD had required surgical treatment compared with patient without CMV infection, and 30% of patients had fatal outcome compared with patients without CMV infection. However, the role of CMV in IBD has been suggested variably as bystanders or pathogens. The treatment strategy for CMV infection in patients with UC has been controversial. More evidence suggested the reactivation of CMV has clinical implication in developing secondary CMV colitis so as to influence the course of the disease and prognosis.
Current clinical guidelines suggest that antiviral therapy be initiated for CMV colitis. 3, [9] [10] [11] [12] [13] Therefore, a proper identification and diagnosis of CMV colitis in active patients with UC is important. Several techniques including endoscopy, histology, serology, viral culture, CMV antigen testing, and CMV DNA testing are used to diagnose CMV infection. 8 CMV colitis is defined as the presence of characteristic intranuclear or intracellular inclusion bodies on hematoxylin and eosin (H&E) stained sections and/or identification of CMV-specific antigen-stained cells from colon biopsy specimens by immunohistochemistry (IHC), which is considered by most to be the current gold standard for diagnosis CMV colitis. 8 The sensitivity is 10% to 87% for HE staining and 78% to 93% for IHC staining. 8, [14] [15] [16] However, histology evaluation has an inherent false negative rate and is an invasive examination technique. 8 The investigation of less-invasive methods to identify CMV colitis is needed. Recent studies suggested a possible correlation between blood CMV DNA real time quantitative polymerase chain reaction (qPCR) or endoscopy features and histologic features from H&E or IHC staining. 8, 17 However, the predictive value of blood CMV DNAqPCR and endoscopic features for the presence and histologic characteristics of CMV colitis are not known.
The aims of our study were to identify endoscopic features of CMV colitis in patients with active UC, to evaluate the association between endoscopic and histologic inflammation scores, and to assess the predictive value of blood CMV DNAqPCR and endoscopic features for CMV colitis.
PATIENTS AND METHODS

Patients
A total of 50 patients with UC (33 men and 17 women) who were with glucocorticoid resistance and/or with frequent disease relapse were tested for CMV infection and enrolled in this study. All patients were diagnosed with UC by clinical, endoscopic, and histological studies. Disease severity in patients with UC was determined clinically by the Truelove and Witts' score and endoscopically by the Mayo endoscopic score as described. 13 CMV infection was confirmed by blood pp65 antigens, CMV Immunoglobulin (Ig) M antibodies, and CMV qPCR. Detailed methods will be described in the next section. This study was approved by the Institutional Review Board of Peking Union Medical College Hospital.
Identification of CMV Infection and CMV Colitis
CMV infection was defined as the presence of positive PCR levels or the detection of CMV antigens or IgM antibodies in serum. Active CMV infection was defined as 2 or more positive as followed by CMV pp65 antigen positive at more than 1 cell per 2 · 10 6 white blood cell, CMV DNA positive at $500 copies/mL by a qPCR DNA test and/or positive CMV IgM antibodies. CMV-pp65 antigen detection was undertaken using the monoclonal antibody indirect immunofluorescence method (CMV Brite Kit, IQ, Groningen, the Netherlands). Peripheral blood human CMV-specific IgM antibody was analyzed by using an enzyme-linked immunosorbent assay method (Captia Cytomegalovirus IgM; Trinity Biotech Plc, Bray, Ireland) and was confirmed by using an anti-CMV enzyme-linked immunosorbent assay (IgM) kit (EI 2570-9601 M; Euroimmun, Luebeck, Germany). Human CMV-DNA was quantified and determined by real-time fluorescence quantitative PCR (RT-PCRfluorescence) (human CMV nucleic acid quantitative assay kit; DAAN Gene Co, China).
CMV colitis was defined as the identification of characteristic intranuclear or intracellular inclusion bodies on H&E sections and/or identification of CMV-specific antigen by IHC, along with clinical symptoms. Full colonoscopy was performed in 17 patients with mild and moderate UC and in 3 patients with severe UC, and sigmoidoscopy was performed in 33 patients with severe UC. Three patients with severe UC with full colonoscopy were the first time to our hospital to confirm the diagnosis and severity. All of the biopsies for HE and IHC staining were taken from the edge of ulcers from left sided colon. 18, 19 The biopsy of base of the ulcer can trigger bleeding, especially in the setting of severe colitis. The histologic evaluation of CMV colitis was performed by pathologists without knowledge of the CMV infection status, treatment status, and patient outcome ( Table 2 ).
The severity of histologic inflammation was scored in a blinded fashion (W.X.Z. and J.C.) as mild (focal active inflammation, i.e., cryptitis), moderate (active inflammation without ulceration, e.g., multiple inflamed crypts and/or crypt abscesses), or severe (ulceration). 20 
Statistical Analysis
Data were expressed as means 6 SD. Chi-square and nonparametric tests were performed to determine the differences between the groups using the SPSS 11.5 software program (IBM, Armonk, NY). For numeric variable relationship analysis, the Spearman correlation coefficient was used. P , 0.05 was considered to be statistically significant.
RESULTS
The Frequency CMV Colitis Rate
The phenotypic characteristics of patient with UC were shown in Table 1 . Among the 50 UC patients with CMV infection, 25 (50.0%) were diagnosed with CMV colitis by identification of characteristic intranuclear or intracellular inclusion bodies on H&E sections and/or CMV-specific antigens-stained mononuclear cells by IHC, along with clinical symptoms (Figure 1 ).
CMV Colitis and the Accuracy of a Blood Assay for Predicting CMV Colitis
The sensitivity of CMV IgM, pp65, and DNA (at 500 copies) for the diagnosis of CMV colitis was 47.1%, 51.5%, and 50.0%, respectively. The specificity of CMV IgM, pp65, and DNA was 16.7%, 25.0%, and 50.0%, respectively. If the cutoff value was set at 1150 copies, then the sensitivity and specificity of DNA for predicting CMV colitis were 44.4% and 78.9%, respectively (0.556 was the area under the curve by receiver operating characteristic analysis).
Clinical Characteristics of UC Patients with or Without CMV Colitis
There were no significant differences in age, sex, smoking habits, family history of IBD, or history of appendectomy between UC patients with or without CMV colitis. However, a higher percentage of severe UC was observed in the group with CMV colitis than controls (Table 1 ).
Among all of the patients with UC, 18 patients (36.0%) had steroid refractory, 7 patients (14.0%) treated with thiopurine immunosuppressants. There was no significant between the 2 groups with and without CMV colitis for disease severity by the Truelove and Witts' score and Mayo endoscopic score. Six patients (12.0%) received colectomy during 2 months. Two patients with CMV colitis received emergency colectomy and no patients without CMV colitis received emergency colectomy in this study.
There was no significant difference between the 2 groups with and without CMV colitis (Table 1) . Among the 25 UC patients with CMV colitis, 18 (76.0%) reported abdominal pain, 25 had diarrhea (100.0%), and 23 complained of hematochezia (92.0%). However, there were no significant differences in frequency of these symptoms between UC patients with or without CMV colitis. Among the 50 patients, 3 patients with CMV colitis developed serious complications compared with 2 patients without CMV colitis. The serious complication included intestinal perforation, intestinal obstruction, toxic megacolon, and gastrointestinal massive hemorrhage. One patient had incomplete intestinal obstruction due to massive colon polyps. There was not significant difference of serious complications between the 2 groups. The levels of inflammatory markers such as erythrocyte sedimentation rate and hypersensitive C reactive protein were not significantly different between the 2 groups.
All 50 patients in this study were received a 14 to 21 days treatment of intravenous ganciclovir (5 mg/kg, q12h). In our preliminary results, frequency of diarrhea and hsCRP did not showed the significant difference between the 2 groups at hospital admission and after intravenous ganciclovir (5 mg/kg) for 2 weeks. However the drop-out value of hsCRP showed significant higher in the patients with CMV colitis than those patients without CMV colitis (29.2 6 39.3 versus 6.4 6 15.2, P ¼ 0.02).
Endoscopic Characteristics of CMV Colitis
Two endoscopists consecutively evaluated the characteristic endoscopic findings, including wide mucosal defect, punched-out ulcers, longitudinal ulcers, irregular ulcers, and cobblestone-like appearance (Fig. 2) . Among the 25 UC patients with CMV colitis, 4 (16.0%) had a wide mucosal defect, 13 (52.0%) had punched-out ulcers, 13 (52.0%) had longitudinal ulcers, 15 (60.0%) had irregular ulcers, and 5 (20.0%) had cobblestone-like appearance (Table 1) .
A significantly higher number of UC patients with CMV colitis had a punched-out ulcers, irregular ulceration, or a cobblestone-like appearance compared with UC patients without CMV colitis (52.0% versus 20.0%, 60.0% versus 16.0%, and 20.0% versus 0.0%, respectively, P , 0.05). Among them, irregular ulcerations appeared higher proportion in patients with severe UC (47.2% versus 0% versus 33.3%, P ¼ 0.044) ( Table 2 ). Among the endoscopic characteristics, the sensitivities of punched-out ulcerations, irregular ulcers, and cobblestone-like appearance in predicting CMV colitis were 52.0%, 60.0%, and 20.0%, and the specificities were 77.0%, 84.0%, and 100.0%, respectively. In addition, the positive predictive values were 68.0%, 80.0%, and 100.0%, and the negative predictive values were 63.0%, 68.0%, and 56.0%, respectively (Table 3) . When we combined these significant endoscopic features, we found the sensitivity, specificity, positive predictive value, and negative predictive value to be 84.0%, 72.0%, 75.0% and 82.0%, respectively.
Histopathological Characteristics of CMV Colitis
Histologic inflammation and the inclusion body count of the biopsy samples were assessed. A higher pathological grade appeared in the CMV colitis group (Table 4) . However, there was no significant difference in pathological grades of severity between 0 to 2 True-love and 3 True-love scores (i.e., disease severity), between 0 to 2 inclusion bodies and .3 inclusion bodies, and between patients with or without certain endoscopic characteristics (Table 4) .
Among all patients with UC, the number of CMV inclusion bodies per high-power field was significantly higher in those with punch-out ulcers than those without punch-out ulcers (P ¼ 0.001) ( Tables 5 and 6 ).
DISCUSSION
In the present study, significantly high proportions of punched-out ulcers, irregular ulcers, and cobblestone-like appearance were observed among the UC patients with CMV colitis. The patients with more than 3 inclusion bodies at the biopsy site were more likely to have a punch-out ulcer on endoscopy. The blood tests for CMV IgM, CMV pp65, and CMV DNA had approximately 50.0% sensitivity values for predicting CMV colitis. When the cutoff value for CMV DNA was set to 1150 copies/mL, the specificity increased to 78.9%.
It is known that CMV reactivation may worsen the clinical condition of UC patients and leads to more complications. 3, 21, 22 Therefore, the identification of CMV colitis in UC patients should be considered. Although histology staining is the standard diagnostic method for CMV colitis, it is subjected to some restrictions, including demanding a colonoscopy test, the choice of biopsy sites, and experience of the pathologists. Typical endoscopic images of various ulcer types, including punched-out ulcer, irregular ulcer, longitudinal ulcer, and cobblestone-like appearance, were reviewed in the literature. 17, 23, 24 CMV is often found in ulcerative lesions in the colon of HIV-infected patients and transplant recipients. 23, 24 The patients of CMV colitis in UC on endoscopy may help predict the presence or absence of CMV colitis in other disease conditions such as HIV infection and post-organ transplant situation. However, previous studies did not find specific endoscopic features in active UC, which might be explained by the different criteria used to define CMV infection or CMV disease. 8, 25, 26 In this study, we observed a significantly higher proportion of punched-out ulcerations, irregular ulcerations, and cobblestone-like appearance among the UC patients with CMV colitis compared with those patients without CMV colitis. Clinicians may need pay more attention to those characteristic endoscopic feature and considered "targeted" biopsy to increase yield of CMV test. At present, there are no published reports on the correlation of endoscopic and pathological features of CMV colitis. In addition, it is not clear to what extent the CMV infection presents typical endoscopic manifestations. Our current study showed that the appearance of punch-out ulceration and longitudinal ulceration were associated with a higher pathological grade of inflammation, with a trend to statistical difference (P ¼ 0.07 and P ¼ 0.073, respectively). More interestingly, the patients with more than 3 inclusion bodies at biopsy site were more prone to having punch-out ulceration, suggesting that a higher viral load is more likely to have inflammation and ulcer on endoscopy and histology. We found that a higher pathological grade appeared more often in the CMV colitis group.
Serum anti-CMV IgM, CMV DNA, and CMV pp65 are major tools for the detection of CMV infection. 24 However, CMV infection may not correlate with actual CMV colitis. CMV infection was defined as isolation of CMV virus or detection of viral proteins or nucleic acid in any body fluid, whereas CMV colitis was defined as the identification of characteristic intranuclear or intracellular inclusion bodies on H&E sections and/or identification of CMV-specific antigen by IHC, along with clinical symptoms. 8, 27 Clinical guidelines suggest antiviral treatment should be initiated in patients with refractory IBD flares, if CMV diagnosis confirmed by tissue IHC. 28 Blood test for CMV infection is noninvasive, simple, and with a high sensitivity. Many studies have reported that blood tests can be used as negative predictors for CMV disease and monitor for the treatment response. [29] [30] [31] However, the predictive value of the blood tests for CMV colitis in patients with UC has not been well defined. In the present study, the blood tests of CMV IgM, pp65, and DNA were compared to evaluate their detection with documentation of colonic CMV on HE staining and/or IHC for CMV colitis. All blood tests showed approximately 50.0% sensitivity for predicting CMV colitis. However, the sensitivity did not change much, but the specificity increased from 50.0% to 78.9%, if the cutoff value for CMV DNA was set to 1150 copies/mL. This suggests that a higher cutoff level CMV DNA copy number may more accurately predict the presence of true CMV colitis. Although the area under the receiver operating characteristic curve was not ideal, qPCR for CMV DNA may be used in clinical practice for predicting CMV colitis. Three studies have shown that higher viral load values correlate with increased risk for CMV disease with 2000 to 5000 copies/mL in patients after transplantation. Another study suggested 1000 IU/mL to detect CMV disease, which was similar with our study. However, the cutoff value might be very variable in difference studies which might be because of different quality control, different disease, and different organs involved, which need to be further studied. [32] [33] [34] [35] [36] There are several limitations of this study. There might have been interobserver variability in scoring UC and CMV colitis. To confirm the quality of the staining, 2 pathologists independently reviewed H&E and IHC stained sections. To ensure the reliability of the results, 80 percent of the sections were also subjected to in situ hybridization, which gave similar diagnostic sensitivity to that of IHC (data not shown). Another limitation of this study is small sample size. Larger prospective studies are needed to be included in the future. Finally, we did not analyze the outcome of antiviral therapy in this report which is a part of ongoing investigations.
In conclusion, we found that the characteristic endoscopic features with punch-out ulcerations and a high load of CMV viremia may help to distinguish CMV colitis from non-CMV colitis in UC. Those features may be useful for predicting the presence of CMV colitis. CMV colitis in patients with UC may be defined by a combination of clinical symptom, CMV viremia characteristic endoscopic, and histologic features. Targeted biopsy may provide a higher yield. This study provides valuable information to help clinicians in assessing CMV colitis and virus load of CMV viremiain patients with UC. The important questions should be asked in the future study are that the clinical significance of CMV infection, CMV colitis and the different virus load in the disease process, and treatment strategy in patients with UC. A prospective, parallel study with a large sample size with a combined assessment of endoscopic, histologic, and serological evaluation is needed to validate the findings of the current study. In addition, the impact of anti-CMV therapy on the disease course of UC needs to be further investigated. 
